Dianthus Therapeutics Q2 net loss widens as R&D costs rise

Dianthus Therapeutics

04/08/2026 21:09

Overview
US biotech firm reported Q2 net loss widened to $50.2 mln
Operating expenses for Q2 rose, driven by higher R&D costs for clinical programs
Company ended Q2 with $1.2 bln in cash, expected to fund operations into 2030

Outlook
Company expects top-line results from Phase 2 MoMeNtum trial in MMN in December '26
Dianthus anticipates Phase 1 healthy volunteer data for DNTH212 by year end '26
DNTH312 aims to be Phase 1 ready by year end '27

Result Drivers
R&D SPENDING - Higher research and development costs driven by increased clinical trial activity and headcount for claseprubart programs
CLINICAL TRIAL PROGRESS - Interim milestones reached for claseprubart in CIDP and MMN, with ongoing and new trials initiated

Company press release: ID:nGNX23rKyg

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$50.22 mln
 
Q2 Income From Operations
 
-$61.48 mln
 
Q2 Operating Expenses
 
$62.24 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Dianthus Therapeutics Inc is $125.00, about 17.9% above its August 3 closing price of $106.02

Reuters Recommended Reads
Aug 4 - Palvella Therapeutics Q2 net loss widens on higher expenses
Aug 3 - Design Therapeutics Q2 net loss narrower than expected
Aug 3 - Keros Therapeutics Q2 net loss narrows on lower expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)